PL1633391T3 - Stabilizowane farmaceutycznie kompozycje peptydowe - Google Patents

Stabilizowane farmaceutycznie kompozycje peptydowe

Info

Publication number
PL1633391T3
PL1633391T3 PL04735873T PL04735873T PL1633391T3 PL 1633391 T3 PL1633391 T3 PL 1633391T3 PL 04735873 T PL04735873 T PL 04735873T PL 04735873 T PL04735873 T PL 04735873T PL 1633391 T3 PL1633391 T3 PL 1633391T3
Authority
PL
Poland
Prior art keywords
peptide compositions
stabilized pharmaceutical
pharmaceutical peptide
stabilized
compositions
Prior art date
Application number
PL04735873T
Other languages
English (en)
Inventor
Claus Juul-Mortensen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1633391T3 publication Critical patent/PL1633391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PL04735873T 2003-06-03 2004-06-03 Stabilizowane farmaceutycznie kompozycje peptydowe PL1633391T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200300820 2003-06-03
US47628203P 2003-06-05 2003-06-05
DKPA200400063 2004-01-19
US53848704P 2004-01-22 2004-01-22
PCT/DK2004/000381 WO2004105790A1 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions
EP04735873A EP1633391B1 (en) 2003-06-03 2004-06-03 Stabilized pharmaceutical peptide compositions

Publications (1)

Publication Number Publication Date
PL1633391T3 true PL1633391T3 (pl) 2012-03-30

Family

ID=33494168

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04735873T PL1633391T3 (pl) 2003-06-03 2004-06-03 Stabilizowane farmaceutycznie kompozycje peptydowe

Country Status (5)

Country Link
US (1) US8114959B2 (pl)
EP (1) EP1633391B1 (pl)
JP (1) JP2007524592A (pl)
PL (1) PL1633391T3 (pl)
WO (1) WO2004105790A1 (pl)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2442223T3 (es) * 2004-08-31 2014-02-10 Novo Nordisk A/S Uso de tris(hidroximetil) aminometano para la estabilización de péptidos, polipéptidos y proteínas
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
ES2779992T3 (es) 2005-12-20 2020-08-21 Univ Duke Métodos y composiciones para suministrar agentes activos con propiedades farmacológicas potenciadas
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2074141B1 (en) 2006-09-22 2016-08-10 Novo Nordisk A/S Protease resistant insulin analogues
SG177953A1 (en) 2007-01-05 2012-02-28 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CN101674812B (zh) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物
KR20100017667A (ko) * 2007-06-01 2010-02-16 노보 노르디스크 에이/에스 안정한 비-수성의 약학 조성물
JP2011504871A (ja) * 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
US20100184059A1 (en) * 2007-06-16 2010-07-22 Enigma Diagnostics Limited Compositions
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
JP5771005B2 (ja) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物
JP5762001B2 (ja) 2008-03-14 2015-08-12 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化インスリンアナログ
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI541023B (zh) 2008-06-17 2016-07-11 印第安納大學科技研究公司 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物
AR072160A1 (es) 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
JP2012512903A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
IN2012DN00377A (pl) 2009-06-16 2015-08-21 Univ Indiana Res & Tech Corp
IN2012DN02120A (pl) 2009-08-14 2015-08-21 Phasebio Pharmaceuticals Inc
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
WO2011094337A1 (en) 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
HUE033656T2 (en) 2010-03-31 2017-12-28 Stabilitech Ltd Binders for stabilizing virus particles
ES2757591T3 (es) 2010-03-31 2020-04-29 Stabilitech Biopharma Ltd Estabilización de partículas virales
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
MX2012013005A (es) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g.
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
US20120046225A1 (en) * 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
EP2717902B1 (en) 2011-06-06 2018-01-24 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
PE20140724A1 (es) 2011-06-22 2014-07-10 Univ Indiana Res & Tech Corp Coagonistas del receptor de glucagon/glp-1
RU2014101697A (ru) 2011-06-22 2015-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Коагонисты рецепторов глюкагона/glp-1
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
CA2847246A1 (en) 2011-11-17 2013-05-23 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
JP6311708B2 (ja) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇｉｐ受容体活性を示すグルカゴンアナローグ
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
US9546205B2 (en) 2012-09-17 2017-01-17 Imperial Innovations Limited Peptide analogues of glucagon and GLP1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CN104902919B (zh) 2012-12-21 2018-11-20 赛诺菲 Glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂
CA2907454C (en) 2013-03-21 2021-05-04 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
SG11201506885UA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of cyclic imide containing peptide products
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016059593A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of protein drugs and process for its preparation
WO2016069409A1 (en) 2014-10-27 2016-05-06 Latitude Pharmaceuticals, Inc. Parenteral glucagon formulations
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN115154591B (zh) 2016-12-16 2023-04-14 诺和诺德股份有限公司 含胰岛素的药物组合物
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
EP3628682A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3897570A1 (en) 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
US20230285584A1 (en) * 2020-05-22 2023-09-14 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
CN116159027A (zh) * 2022-12-29 2023-05-26 江苏诺泰澳赛诺生物制药股份有限公司 一种司美格鲁肽冻干药物组合物及其制备方法

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
AU616411B2 (en) 1987-05-14 1991-10-31 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DE69307505T2 (de) 1992-05-13 1997-07-24 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
PT729362E (pt) 1993-11-19 2000-06-30 Searle & Co Composicao transdermica de n-¬n-¬5-¬4-(aminoiminometil)fenil|-1oxopentil|-l-alfa-aspartil|-l-fenillalanina ou esteres e seus sais farmaceuticamente aceitaveis
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
ES2211889T3 (es) 1994-08-31 2004-07-16 Mitsubishi Pharma Corporation Procedimiento para la purificacion de albumina de suero recombinante.
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (ja) 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ 遅延性ｇｌｐ−１組成物
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DK0828753T3 (da) 1995-06-02 2003-06-30 Novozymes As A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
CA2278199A1 (en) 1997-01-20 1998-07-23 Japan Energy Corporation Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE69738333T2 (de) 1997-10-01 2008-11-27 Novadel Pharma Inc. Nichtpolares Spray zur bukkalen Verabreichung
EP1025126B1 (en) 1997-10-24 2003-04-16 Genentech, Inc. Purification of molecules
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
ATE466028T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As N-terminal veränderte glp-1 abkömmlinge
US6245572B1 (en) 1998-05-01 2001-06-12 University Of Tennessee Research Corporation Flow cytometric characterization of amyloid fibrils
US6440930B1 (en) 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
ES2249933T3 (es) * 1998-12-22 2006-04-01 Eli Lilly And Company Formulacion autoestable de peptido 1 tipo glucagon.
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
WO2000055119A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
CA2369839A1 (en) 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
EP1242121B1 (en) 1999-12-16 2005-02-09 Eli Lilly And Company Polypeptide compositions with improved stability
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
EP1257577B1 (en) 2000-01-27 2004-04-21 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
DZ3388A1 (fr) 2000-06-16 2001-12-27 Lilly Co Eli Analogues de peptide 1 du type glucagon
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
MXPA03005135A (es) 2000-12-13 2003-12-04 Lilly Co Eli Regimen de tratamiento cronico usando peptidos insulinotropicos similares al glucagon.
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4280070B2 (ja) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
US6573237B2 (en) * 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd PROTEIN PREPARATION
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
EP1344533B1 (en) 2002-03-15 2006-08-23 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
ES2308029T3 (es) 2002-09-25 2008-12-01 Novo Nordisk A/S Proceso de purificacion que comprende una microfiltracion a temperaturas elevadas.
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
MXPA05013048A (es) 2003-06-03 2006-03-02 Novo Nordisk As Composiciones peptodicas farmaceuticas estabilizadas.
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
EP1684793B1 (en) 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Also Published As

Publication number Publication date
WO2004105790A1 (en) 2004-12-09
US20080318865A1 (en) 2008-12-25
JP2007524592A (ja) 2007-08-30
EP1633391A1 (en) 2006-03-15
US8114959B2 (en) 2012-02-14
EP1633391B1 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
PL1633391T3 (pl) Stabilizowane farmaceutycznie kompozycje peptydowe
PL1633390T3 (pl) Stabilizowane kompozycje farmaceutyczne peptydu glp-1
GB2389530B (en) Pharmaceutical compositions
GB0320382D0 (en) Pharmaceutical compositions
GB0327723D0 (en) Pharmaceutical compositions
AU2003302603A8 (en) Improved opioid pharmaceutical compositions
AU2003291103A8 (en) Pharmaceutical composition
ZA200605080B (en) Pharmaceutical compositions
GB2391473B (en) Pharmaceutical compositions
HU0301154D0 (en) Pharmaceutical composition
GB0300531D0 (en) Pharmaceutical compositions
GB0300427D0 (en) Pharmaceutical composition
AU2003250372A8 (en) Pharmaceutical composition
HK1084670A1 (en) Pharmaceutical compositions comprising cabbinochreme type compounds
EP1648411A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0307866D0 (en) Pharmaceutical composition
EP1699458A4 (en) PHARMACEUTICAL COMPOSITION
GB0329232D0 (en) Pharmaceutical composition
GB0317663D0 (en) Pharmaceutical composition
HU0302441D0 (en) Pharmaceutical compositions having antibiothic effect
GB0213481D0 (en) Pharmaceutical compositions
GB0300885D0 (en) Pharmaceutical composition
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
GB0306933D0 (en) Pharmaceutical composition
GB0305579D0 (en) Pharmaceutical compositions